| |
PRZOOM - /newswire/ -
Austin, TX, United States, 2009/04/23 - nanoTox Chief Scientific Officer, Dr. David W. Hobson, will speak on regulations and policies affecting nanotech companies the NSTI Nanotech conference in Houston, Texas, on May 5.
|
| |
nanoTox Inc., the first company to provide complete risk assessment – and solutions – exclusively for nanoparticles, announced today that its Chief Scientific Officer, Dr. David W. Hobson, will share his insight on impending regulations and policies surrounding nanotech product safety during the NSTI Nanotech conference and exposition in Houston, Texas. The panel, entitled “Nanotech Policy, Regulation and Product Safety,” will take place at 1:30 pm on May 5, 2009 at the George R. Brown Convention Center.
Dr. Hobson is a toxicological expert on safety issues related to the commercialization of nanotechnology and is a noted consultant to government and industry on nanoproduct and nanotechnology development issues.
"The nanotechnology platform is demonstrating amazing potential for the development of advanced technologies and products in many business sectors," stated Dr. Hobson. "Recent actions in the U.S. and abroad requiring nanotechnology companies to list certain materials they incorporate into commercial products are just the start of events that will have lasting effects on nanotechnology companies and the marketplace for nanoproducts."
Dr. Hobson has 30 years of practical experience in toxicological research and development, including environmental, industrial, and medical projects for government, industry and private concerns. His experience with nanomaterials includes pharmacological and toxicological research using in vitro and in vivo pre-clinical models; preparation of medical device submissions to regulatory agencies, as well as chemistry and manufacturing controls and pharmacology/toxicology sections for new drug applications. His work with nanoTox includes establishing state-of-the-art facilities and test procedures, which are employed for clients under strict confidentiality and in accordance with established U.S. good laboratory practices and international data quality standards.
Dr. Hobson is a past president of the American College of Toxicology and an editorial advisor to the International Journal of Toxicology. He teaches courses in biophysics, nuclear pharmacy, immunoassay and radiation biology at the University of the Incarnate Word in San Antonio.
Dr. Hobson has many scientific publications to his credit including the book Dermal and Ocular Toxicology: Fundamentals and Methods; and book chapters on product risk assessment, toxicology study design, toxicology of wound healing, dermal toxicology and gastrointestinal toxicology. He has led successful projects including all aspects of pharmaceutical development – from discovery, development and registration to post-market support – which have resulted in currently marketed pharmaceutical products and numerous patents.
nanoTox will be exhibiting at the NSTI Nanotech conference and exposition May 3-7, 2009. The nanoTox booth, #907, will be located near the front of the exhibit hall.
About nanoTox
nanoTox (nanotox.com) is the first company to provide complete risk assessment – and solutions – exclusively for nanoparticles. nanoTox determines the toxicity of its clients’ nanoproducts and offers strategies for managing, reducing or eliminating risk to meet state and federal safety guidelines and shorten time to market. Because nanoTox uses methodologies that are performed under recognized international data quality standards (GLP, ISO, etc.) in its laboratories, the results and associated assessments are suitable for use to support regulatory decisions, product registrations, litigation, and for acceptance by the insurance industry.
nanoTox ensures complete client confidentiality for all of its clients, which include companies or entities that require government approval to market their nanoproducts, venture capital firms that invest in nanoproduct companies, law firms engaged by such companies and insurance companies considering insuring such companies from liability.
nanoTox is headquartered in Austin, Texas, with offices in Maastricht, Netherlands.
About NSTI
The Nano Science and Technology Institute advances and integrates nano and other advanced technologies through education, conventions, business publishing, and research services. NSTI produces the annual Nanotechnology conference and trade show, which attracts more than 5,000 industrial, academic, business and governmental attendees from around the world. It is the largest gathering of the nanotechnology industry in the U.S. NSTI was founded in 1997 as a result of the merger between various scientific societies, and is headquartered in Cambridge, Massachusetts with offices in California and Switzerland.
|
lwright[.]cameronweeks.com 
